Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine

Published on :

Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine Canadian government commits to purchase 52 million doses with option for additional 24 million of Novavax candidate vaccine, [….]

RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing

Published on :

FREDERICK, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks, highly engineered media and hMSC bioprocess systems, today announces the signing of a strategic collaboration with Sartorius, a leading international partner of life science research and the biopharmaceutical industry. The collaboration aims to…

Novavax taps Baxter for commercial production as COVID-19 vaccine nears finish line

Published on :

Novavax tapped Baxter BioPharma Solutions to support commercial-scale vaccine manufacturing at its facility in Halle, Germany. Once manufacturing work kicks off, Baxter will be on deck to crank out supplies for the European and U.K. markets, the companies said.

Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers

Published on :

 Novel liquid biopsy technology combines machine learning and low-cost cell free DNA genome-wide fragmentation profiles BALTIMORE, January 12, 2021 /PRNewsire/ — Delfi Diagnostics, Inc., a pioneering developer of a new class [….]

Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat Heparin-Inducted Thrombocytopenia

Published on :

Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced it submitted an Investigational New Drug  (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a Phase 1 clinical trial of VLX-1005, a first-in-class small molecule inhibitor of 12-Lipoxygenase in development for the treatment of heparin-induced thrombocytopenia (HIT).

Rockville’s Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform

Published on :

– Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON & [….]